Octreotide

• Description :

  Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly[1][2].

• Product Name Alternative :

  SMS 201-995

• UNSPSC :

  12352209

• Hazard Statement :

  H315, H319, H320

• Target :

  Apoptosis; Somatostatin Receptor

• Type :

  Peptides

• Related Pathways :

  Apoptosis; GPCR/G Protein; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Octreotide.html

• Purity :

  99.96

• Solubility :

  H2O : ≥ 50 mg/mL

• Smiles :

  O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=CC=C3)N[C@@H]1CC4=CNC5=CC=CC=C45

• Molecular Formula :

  C49H66N10O10S2

• Molecular Weight :

  1019.24

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Wang XX, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet?induced obesity. Mol Med Rep. 2017 Jul;16 (1) :109-118|[2]Kugita M, et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12 (5) :e0177934.|[3]Xiao-Xia Wang, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity. Mol Med Rep. 2017 Jul;16 (1) :109-118.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Peptides

• Clinical Information :

  Launched

• Isoform :

  SSTR2; SSTR3; SSTR5

• Citation 01 :

  Basic Clin Pharmacol Toxicol. 2022 Sep;131 (3) :174-188.|Biomacromolecules. 2024 May 13;25 (5) :2749-2761.|Cell Mol Bioeng. 2022 Dec 22;16 (1) :55-67.|Eur J Nucl Med Mol Imaging. 2024 Nov;51 (13) :4099-4110.|Faculty of Biological and Environmental Sciences. University of Helsinki Finland. 2018 Dec.|J Pharm Biomed Anal. 2022 Mar 20:211:114518.|J Pharm Biomed Anal. 2023 Feb 5:224:115156.|J Pharm Sci. 2022 Dec;111 (12) :3417-3423.|Mol Cancer. 2024 Sep 20;23 (1) :205.|J Biol Chem. 2025 Jul 30;301 (9) :110544.|Mol Med Rep. 2024 Jun;29 (6) :90.|Nat Commun. 2023 Feb 21;14 (1) :962.|Patent. US20240307504A1.|Research Square Print. 2022 Aug.

• CAS Number :

  [83150-76-9]